<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLOMIPHENE CITRATE - clomiphene citrate tablet </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<h1>
<span class="Bold">Clomiphene Citrate Tablets USP<br></span>Revised: June 2004<br><span class="Bold">Rx only</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_63c9f9bf-aedb-4834-9def-a46dfff9db9f"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Clomiphene citrate tablets USP is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy] triethylamine citrate (1:1). It has the molecular formula of C<span class="Sub">26</span>H<span class="Sub">28</span>ClNO • C<span class="Sub">6</span>H<span class="Sub">8</span>O<span class="Sub">7</span> and a molecular weight of 598.09. It is represented structurally as:</p>
<div class="Figure">
<img alt="Structural formula for clomiphene citrate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53eff40f-37b1-47b1-a9b8-c22360855f18&amp;name=clomiphene-citrate-tablets-usp-1.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Clomiphene citrate is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, essentially odorless, crystalline powder. It is freely soluble in methanol; soluble in ethanol; slightly soluble in acetone, water, and chloroform; and insoluble in ether.</p>
<p>Clomiphene citrate tablets USP is a mixture of two geometric isomers [cis (zuclomiphene) and trans (enclomiphene)] containing between 30% and 50% of the cis-isomer.</p>
<p>Each white scored tablet contains 50 mg clomiphene citrate USP. The tablet also contains the following inactive ingredients: corn starch, lactose, magnesium stearate, pregelatinized corn starch, and sucrose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_0e3694f1-031f-4db7-a8bf-2346fd8de8e8"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_d5dbaf57-ed54-440b-9420-02a389bc564d"></a><a name="section-2.1"></a><p></p>
<h2><span class="Underline">Action</span></h2>
<p class="First">Clomiphene citrate tablets USP is a drug of considerable pharmacologic potency. With careful selection and proper management of the patient, clomiphene citrate tablets USP has been demonstrated to be a useful therapy for the anovulatory patient desiring pregnancy.</p>
<p>Clomiphene citrate is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix. It may compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. Clomiphene citrate initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture. The first endocrine event in response to a course of clomiphene therapy is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis, resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> as they would in a normal ovulatory cycle.</p>
<p>Available data suggest that both the estrogenic and antiestrogenic properties of clomiphene may participate in the initiation of ovulation. The two clomiphene isomers have been found to have mixed estrogenic and antiestrogenic effects, which may vary from one species to another. Some data suggest that zuclomiphene has greater estrogenic activity than enclomiphene.</p>
<p>Clomiphene citrate has no apparent progestational, androgenic, or antiandrogenic effects and does not appear to interfere with pituitary-adrenal or pituitary-thyroid function.</p>
<p>Although there is no evidence of a "carryover effect" of clomiphene citrate tablets USP, spontaneous ovulatory menses have been noted in some patients after clomiphene citrate tablets USP therapy.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_4664e341-0b8c-4765-8c91-a814f5e05454"></a><a name="section-2.2"></a><p></p>
<h2><span class="Underline">Pharmacokinetics</span></h2>
<p class="First">Based on early studies with <span class="Sup">14</span>C-labeled clomiphene citrate, the drug was shown to be readily absorbed orally in humans and excreted principally in the feces. Cumulative urinary and fecal excretion of the <span class="Sup">14</span>C averaged about 50% of the oral dose and 37% of an intravenous dose after 5 days. Mean urinary excretion was approximately 8% with fecal excretion of about 42%.</p>
<p>Some <span class="Sup">14</span>C label was still present in the feces 6 weeks after administration. Subsequent single-dose studies in normal volunteers showed that zuclomiphene (cis) has a longer half-life than enclomiphene (trans). Detectable levels of zuclomiphene persisted for longer than a month in these subjects. This may be suggestive of stereo-specific enterohepatic recycling or sequestering of the zuclomiphene. Thus, it is possible that some active drug may remain in the body during early pregnancy in women who conceive in the menstrual cycle during clomiphene citrate tablets USP therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_b0a9062a-3714-450e-b384-3a8da939f738"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">During clinical investigations, 7578 patients received clomiphene citrate tablets USP, some of whom had impediments to ovulation other than ovulatory dysfunction (see <a href="#LINK_a47e2626-8803-4d03-8a3a-de8f6b332ce1">INDICATIONS AND USAGE</a>). In those clinical trials, successful therapy characterized by pregnancy occurred in approximately 30% of these patients.</p>
<p>There were a total of 2635 pregnancies reported during the clinical trial period. Of those pregnancies, information on outcome was only available for 2369 of the cases. Table 1 summarizes the outcome of these cases.</p>
<p>Of the reported pregnancies, the incidence of multiple pregnancies was 7.98%: 6.9% twin, 0.5% triplet, 0.3% quadruplet, and 0.1% quintuplet. Of the 165 twin pregnancies for which sufficient information was available, the ratio of monozygotic to dizygotic twins was about 1:5. Table 1 reports the survival rate of the live multiple births.</p>
<p>A sextuplet birth was reported after completion of original clinical studies; none of the sextuplets survived (each weighed less than 400 g), although each appeared grossly normal.</p>
<a name="i0a93af71-a8ac-4af1-82d9-04af5bd84e1a"></a><table>
<caption><span>Table 1. Outcome of Reported Pregnancies in Clinical Trials (n = 2369)</span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<th class="Lrule">Outcome</th>
<th class="Lrule" align="center">Total Number of Pregnancies</th>
<th class="Lrule Rrule">Survival Rate</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule"> Pregnancy Wastage</td>
<td class="Lrule" align="center"> </td>
<td class="Lrule Rrule"> </td>
</tr>
<tr>
<td class="Lrule">   <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">Spontaneous Abortions</span></td>
<td class="Lrule" align="center"> 483*</td>
<td class="Lrule Rrule"> </td>
</tr>
<tr>
<td class="Botrule Lrule">   <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">Stillbirths</span></td>
<td class="Botrule Lrule" align="center">  24</td>
<td class="Botrule Lrule Rrule"> </td>
</tr>
<tr>
<td class="Lrule"> Live Births</td>
<td class="Lrule" align="center"> </td>
<td class="Lrule Rrule"> </td>
</tr>
<tr>
<td class="Lrule">   Single Births</td>
<td class="Lrule" align="center"> 1697</td>
<td class="Lrule Rrule"> 98.16%<span class="Sup">†</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule">   Multiple Births</td>
<td class="Lrule" align="center"> 165</td>
<td class="Lrule Rrule"> 83.26%<span class="Sup">†</span>
</td>
</tr>
</tbody>
</table>
<p>* Includes 28 ectopic pregnancies, 4 hydatiform moles, and 1 fetus papyraceous.<br><span class="Sup">†</span> Indicates percentage of surviving infants from these pregnancies.</p>
<p>The overall survival of infants from multiple pregnancies including <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>, and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> is 73%.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_a47e2626-8803-4d03-8a3a-de8f6b332ce1"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Clomiphene citrate tablets USP is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate tablets USP therapy. Those patients most likely to achieve success with clomiphene therapy include patients with <span class="product-label-link" type="condition" conceptid="195501" conceptname="Polycystic ovaries">polycystic ovary</span> syndrome (see <a href="#LINK_9c02db35-383e-45c4-b6ea-9a39d6a5bd55">WARNINGS: <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian Hyperstimulation Syndrome</span></a>), <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>-<span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span> syndrome, psychogenic <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, post-oral-contraceptive <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, and certain cases of secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> of undetermined etiology.</p>
<p>Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate tablets USP should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See <a href="#LINK_4dbb5bf6-c45e-45ec-98b1-09d6ceed5068">DOSAGE AND ADMINISTRATION</a> and <a href="#LINK_fe21a01b-de53-4a61-a2cc-93ab8837a65b">PRECAUTIONS</a>.) </p>
<p>Clomiphene citrate tablets USP is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see <a href="#LINK_ff40eb95-cda3-47eb-ae53-676800590cf2">CONTRAINDICATIONS</a>):</p>
<ol class="Arabic">
<li>Patients who are not pregnant. 
</li>
<li>Patients without <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span>. Clomiphene citrate tablets USP should not be used in patients with <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">ovarian enlargement</span> except those with <span class="product-label-link" type="condition" conceptid="195501" conceptname="Polycystic ovaries">polycystic ovary</span> syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate tablets USP treatment. 
</li>
<li>Patients without abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. If abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. 
</li>
<li>Patients with normal liver function.</li>
</ol>
<p>In addition, patients selected for clomiphene citrate tablets USP therapy should be evaluated in regard to the following:</p>
<ol class="Arabic">
<li>
<span class="Bold">Estrogen Levels.</span> Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. 
</li>
<li>
<span class="Bold">Primary Pituitary or <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">Ovarian Failure</span>.</span> Clomiphene citrate tablets USP therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. 
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> and Endometrial Carcinoma.</span> The incidence of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate tablets USP therapy in this population. 
</li>
<li>
<span class="Bold">Other Impediments to Pregnancy.</span> Impediments to pregnancy can include <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span>, adrenal disorders, <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span>, and male factor <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>. 
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">Uterine Fibroids</span>.</span> Caution should be exercised when using clomiphene citrate tablets USP in patients with <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">uterine fibroids</span> due to the potential for further enlargement of the <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">fibroids</span>.</li>
</ol>
<p>There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate tablets USP in the treatment of male <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>. In addition, testicular tumors and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate tablets USP is not known.</p>
<p>Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate tablets USP in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate tablets USP regimen for ovulation induction in <span class="Italics">in vitro</span> fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate tablets USP is not recommended for these uses.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_ff40eb95-cda3-47eb-ae53-676800590cf2"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3f3fded8-0815-4793-8308-e66f4caf9eb8"></a><a name="section-5.1"></a><p></p>
<h2><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></h2>
<p class="First">Clomiphene citrate tablets USP is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to clomiphene citrate or to any of its ingredients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e3fe5241-bacc-4a55-bb7c-81e8af4461ca"></a><a name="section-5.2"></a><p></p>
<h2><span class="Underline">Pregnancy</span></h2>
<p class="First">Clomiphene citrate tablets USP should not be administered during pregnancy. Clomiphene citrate tablets USP may cause fetal harm in animals (see <a href="#LINK_fa990191-e1ea-4970-9ebf-4b8f8ada13ad">Animal Fetotoxicity</a>). Although no causative evidence of a deleterious effect of clomiphene citrate tablets USP therapy on the human fetus has been established, there have been reports of birth anomalies which, during clinical studies, occurred at an incidence within the range reported for the general population (see <a href="#LINK_0b9b7d54-75c2-4ccc-814b-c4cd3f7c1a10">Fetal/Neonatal Anomalies and Mortality; ADVERSE REACTIONS</a>).</p>
<p>To avoid inadvertent clomiphene citrate tablets USP administration during early pregnancy, appropriate tests should be utilized during each treatment cycle to determine whether ovulation occurs. The patient should be evaluated carefully to exclude pregnancy, <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">ovarian enlargement</span>, or <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cyst</span> formation between each treatment cycle. The next course of clomiphene citrate tablets USP therapy should be delayed until these conditions have been excluded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c09adf56-2134-49e5-9211-9315a2612328"></a><a name="section-5.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Fetal/Neonatal Anomalies and Mortality.</span> The following fetal abnormalities have been reported subsequent to pregnancies following ovulation induction therapy with clomiphene citrate tablets USP during clinical trials. Each of the following fetal abnormalities were reported at a rate of &lt;1% (experiences are listed in order of decreasing frequency): Congenital heart lesions, Down syndrome, club foot, congenital gut lesions, <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span>, <span class="product-label-link" type="condition" conceptid="381114" conceptname="Microcephalus">microcephaly</span>, harelip and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, congenital hip, <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span>, <span class="product-label-link" type="condition" conceptid="437655" conceptname="Undescended testicle">undescended testicles</span>, <span class="product-label-link" type="condition" conceptid="74740" conceptname="Polydactyly">polydactyly</span>, conjoined twins and teratomatous malformation, <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span>, <span class="product-label-link" type="condition" conceptid="4290687" conceptname="Amaurosis">amaurosis</span>, <span class="product-label-link" type="condition" conceptid="4029967" conceptname="Arteriovenous fistula">arteriovenous fistula</span>, <span class="product-label-link" type="condition" conceptid="4288544" conceptname="Inguinal hernia">inguinal hernia</span>, <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernia</span>, <span class="product-label-link" type="condition" conceptid="4162283" conceptname="Syndactyly">syndactyly</span>, pectus excavatum, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, <span class="product-label-link" type="condition" conceptid="4218306" conceptname="Dermoid cyst">dermoid cyst</span> of scalp, <span class="product-label-link" type="condition" conceptid="4077297" conceptname="Congenital omphalocele">omphalocele</span>, <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> occulta, <span class="product-label-link" type="condition" conceptid="134743" conceptname="Congenital ichthyosis of skin">ichthyosis</span>, and persistent lingual frenulum. Neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> in infants with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> have also been reported at a rate of &lt;1%. The overall incidence of reported birth anomalies from pregnancies associated with maternal clomiphene citrate tablets USP ingestion during clinical studies was within the range of that reported for the general population.</p>
<p>In addition, reports of birth anomalies have been received during postmarketing surveillance of clomiphene citrate tablets USP (see <a href="#LINK_bab349a9-eb75-4dc1-8e35-87032c0c0005">ADVERSE REACTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fa990191-e1ea-4970-9ebf-4b8f8ada13ad"></a><a name="section-5.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Animal Fetotoxicity.</span> Oral administration of clomiphene citrate to pregnant rats during organogenesis at doses of 1 to 2 mg/kg/day resulted in hydramnion and weak, edematous fetuses with wavy ribs and other temporary bone changes. Doses of 8 mg/kg/day or more also caused increased resorptions and dead fetuses, dystocia, and delayed parturition, and 40 mg/kg/day resulted in increased maternal mortality. Single doses of 50 mg/kg caused fetal <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, while 200 mg/kg caused <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>.</p>
<p>Following injection of clomiphene citrate 2 mg/kg to mice and rats during pregnancy, the offspring exhibited metaplastic changes of the reproductive tract. Newborn mice and rats injected during the first few days of life also developed metaplastic changes in uterine and vaginal mucosa, as well as premature vaginal opening and anovulatory ovaries. These findings are similar to the abnormal reproductive behavior and <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> described with other estrogens and antiestrogens.</p>
<p>In rabbits, some temporary bone alterations were seen in fetuses from dams given oral doses of 20 or 40 mg/kg/day during pregnancy, but not following 8 mg/kg/day. No permanent malformations were observed in those studies. Also, rhesus monkeys given oral doses of 1.5 to 4.5 mg/kg/day for various periods during pregnancy did not have any abnormal offspring.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d57f0100-b77f-4a85-ad7f-429118baba9e"></a><a name="section-5.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Liver Disease.</span> Clomiphene citrate tablets USP therapy is contraindicated in patients with liver disease or a history of liver dysfunction (see also <a href="#LINK_a47e2626-8803-4d03-8a3a-de8f6b332ce1">INDICATIONS AND USAGE</a> and <a href="#LINK_bab349a9-eb75-4dc1-8e35-87032c0c0005">ADVERSE REACTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_87c9a226-af6e-4e3a-bf87-9042f9b6f111"></a><a name="section-5.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span>.</span> Clomiphene citrate tablets USP is contraindicated in patients with abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> of undetermined origin (see <a href="#LINK_a47e2626-8803-4d03-8a3a-de8f6b332ce1">INDICATIONS AND USAGE</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_41434f18-61da-47c8-a54f-1e6707c620cb"></a><a name="section-5.7"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian Cysts</span>.</span> Clomiphene citrate tablets USP is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span> or enlargement not due to polycystic ovarian syndrome (see <a href="#LINK_a47e2626-8803-4d03-8a3a-de8f6b332ce1">INDICATIONS AND USAGE</a> and <a href="#LINK_98950fff-e14e-41d4-b4c8-1ef6da081a42">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1e48c66a-a11c-4b6c-9d27-ddefaaa7ab93"></a><a name="section-5.8"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Other.</span> Clomiphene citrate tablets USP is contraindicated in patients with uncontrolled thyroid or adrenal dysfunction or in the presence of an organic intracranial lesion such as pituitary tumor (see <a href="#LINK_a47e2626-8803-4d03-8a3a-de8f6b332ce1">INDICATIONS AND USAGE</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_98950fff-e14e-41d4-b4c8-1ef6da081a42"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4904aea1-8e33-450e-8268-6086ff3901b8"></a><a name="section-6.1"></a><p></p>
<h2><span class="Underline">Visual Symptoms</span></h2>
<p class="First">Patients should be advised that blurring or other visual symptoms such as spots or flashes (scintillating scotomata) may occasionally occur during therapy with clomiphene citrate tablets USP. These visual symptoms increase in incidence with increasing total dose or therapy duration and generally disappear within a few days or weeks after clomiphene citrate tablets USP is discontinued. Patients should be warned that these visual symptoms may render such activities as driving a car or operating machinery more hazardous than usual, particularly under conditions of variable lighting.</p>
<p>These visual symptoms appear to be due to intensification and prolongation of afterimages. Symptoms often first appear or are accentuated with exposure to a brightly lit environment. While measured visual acuity usually has not been affected, a study patient taking 200 mg clomiphene citrate tablets USP daily developed visual blurring on the 7th day of treatment, which progressed to severe diminution of visual acuity by the 10th day. No other abnormality was found, and the visual acuity returned to normal on the 3rd day after treatment was stopped.</p>
<p>Ophthalmologically definable scotomata and retinal cell function (electroretinographic) changes have also been reported. A patient treated during clinical studies developed phosphenes and scotomata during prolonged clomiphene citrate tablets USP administration, which disappeared by the 32nd day after stopping therapy.</p>
<p>Postmarketing surveillance of adverse events has also revealed other visual signs and symptoms during clomiphene citrate tablets USP therapy (see <a href="#LINK_bab349a9-eb75-4dc1-8e35-87032c0c0005">ADVERSE REACTIONS</a>).</p>
<p>While the etiology of these visual symptoms is not yet understood, patients with any visual symptoms should discontinue treatment and have a complete ophthalmological evaluation carried out promptly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9c02db35-383e-45c4-b6ea-9a39d6a5bd55"></a><a name="section-6.2"></a><p></p>
<h2><span class="Underline"><span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian Hyperstimulation Syndrome</span></span></h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">ovarian hyperstimulation syndrome</span> (OHSS) has been reported to occur in patients receiving clomiphene citrate therapy for ovulation induction. In some cases, OHSS occurred following cyclic use of clomiphene citrate therapy or when clomiphene citrate was used in combination with gonadotropins. Transient liver function test abnormalities suggestive of hepatic dysfunction, which may be accompanied by morphologic changes on liver biopsy, have been reported in association with <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">ovarian hyperstimulation syndrome</span> (OHSS).</p>
<p>OHSS is a medical event distinct from uncomplicated <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">ovarian enlargement</span>. The clinical signs of this syndrome in severe cases can include gross <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">ovarian enlargement</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>. In addition, the following symptoms have been reported in association with this syndrome: <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">anasarca</span>, <span class="product-label-link" type="condition" conceptid="4195440" conceptname="Hydrothorax">hydrothorax</span>, <span class="product-label-link" type="condition" conceptid="4241033" conceptname="Acute abdomen">acute abdomen</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, intraperitoneal and ovarian <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, torsion of the ovary, and acute <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>. The early warning signs of OHSS are <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Elevated urinary steroid levels, varying degrees of <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, hemoconcentration, and <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> may occur. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to <span class="product-label-link" type="condition" conceptid="4192647" conceptname="Hypovolemic shock">hypovolemic shock</span>, hemoconcentration, or <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> has occurred. Due to fragility of enlarged ovaries in severe cases, abdominal and pelvic examination should be performed very cautiously. If conception results, rapid progression to the severe form of the syndrome may occur.</p>
<p>To minimize the hazard associated with occasional abnormal <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">ovarian enlargement</span> associated with clomiphene citrate tablets USP therapy, the lowest dose consistent with expected clinical results should be used. Maximal enlargement of the ovary, whether physiologic or abnormal, may not occur until several days after discontinuation of the recommended dose of clomiphene citrate tablets USP. Some patients with <span class="product-label-link" type="condition" conceptid="195501" conceptname="Polycystic ovaries">polycystic ovary</span> syndrome who are unusually sensitive to gonadotropin may have an exaggerated response to usual doses of clomiphene citrate tablets USP. Therefore, patients with <span class="product-label-link" type="condition" conceptid="195501" conceptname="Polycystic ovaries">polycystic ovary</span> syndrome should be started on the lowest recommended dose and shortest treatment duration for the first course of therapy (see <a href="#LINK_4dbb5bf6-c45e-45ec-98b1-09d6ceed5068">DOSAGE AND ADMINISTRATION</a>).</p>
<p>If enlargement of the ovary occurs, additional clomiphene citrate tablets USP therapy should not be given until the ovaries have returned to pretreatment size, and the dosage or duration of the next course should be reduced. <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">Ovarian enlargement</span> and <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> formation associated with clomiphene citrate tablets USP therapy usually regress spontaneously within a few days or weeks after discontinuing treatment. The potential benefit of subsequent clomiphene citrate tablets USP therapy in these cases should exceed the risk. Unless surgical indication for laparotomy exists, such cystic enlargement should always be managed conservatively.</p>
<p>A causal relationship between <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">ovarian hyperstimulation</span> and ovarian cancer has not been determined. However, because a correlation between ovarian cancer and nulliparity, <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, and age has been suggested, if <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span> do not regress spontaneously, a thorough evaluation should be performed to rule out the presence of <span class="product-label-link" type="condition" conceptid="200675" conceptname="Neoplasm of uncertain behavior of ovary">ovarian neoplasia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_fe21a01b-de53-4a61-a2cc-93ab8837a65b"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_abae0b40-817d-4205-b163-22cdfa8f63bb"></a><a name="section-7.1"></a><p></p>
<h2><span class="Underline">General</span></h2>
<p class="First">Careful attention should be given to the selection of candidates for clomiphene citrate tablets USP therapy. Pelvic examination is necessary prior to clomiphene citrate tablets USP treatment and before each subsequent course (see <a href="#LINK_ff40eb95-cda3-47eb-ae53-676800590cf2">CONTRAINDICATIONS</a> and <a href="#LINK_98950fff-e14e-41d4-b4c8-1ef6da081a42">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_9080b477-98a5-4f89-a534-61dda200fb17"></a><a name="section-7.2"></a><p></p>
<h2><span class="Underline">Information for Patients</span></h2>
<p class="First">The purpose and risks of clomiphene citrate tablets USP therapy should be presented to the patient before starting treatment. It should be emphasized that the goal of clomiphene citrate tablets USP therapy is ovulation for subsequent pregnancy. The physician should counsel the patient with special regard to the following potential risks:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2c5161e0-48a9-493b-a337-8e943d146957"></a><a name="section-7.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Visual Symptoms:</span> Advise that blurring or other visual symptoms occasionally may occur during or shortly after clomiphene citrate tablets USP therapy. Warn that visual symptoms may render such activities as driving a car or operating machinery more hazardous than usual, particularly under conditions of variable lighting (see <a href="#LINK_98950fff-e14e-41d4-b4c8-1ef6da081a42">WARNINGS</a>).</p>
<p>The patient should be instructed to inform the physician whenever any unusual visual symptoms occur. If the patient has any visual symptoms, treatment should be discontinued and complete ophthalmologic evaluation performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3dcd48a2-9ddb-45f2-9bf0-1acdf9de4314"></a><a name="section-7.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Abdominal/<span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic Pain</span> or <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Distention</span>:</span> <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">Ovarian enlargement</span> may occur during or shortly after therapy with clomiphene citrate tablets USP. To minimize the risks associated with <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">ovarian enlargement</span>, the patient should be instructed to inform the physician of any abdominal or <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, or <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> after taking clomiphene citrate tablets USP (see <a href="#LINK_98950fff-e14e-41d4-b4c8-1ef6da081a42">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bbfaaeea-6cf7-4f02-94c1-857338819cf4"></a><a name="section-7.2.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432969" conceptname="Multiple pregnancy">Multiple Pregnancy</span>:</span> Inform the patient that there is an increased chance of <span class="product-label-link" type="condition" conceptid="432969" conceptname="Multiple pregnancy">multiple pregnancy</span>, including bilateral <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">tubal pregnancy</span> and coexisting tubal and intrauterine pregnancy, when conception occurs in relation to clomiphene citrate tablets USP therapy. The potential complications and hazards of <span class="product-label-link" type="condition" conceptid="432969" conceptname="Multiple pregnancy">multiple pregnancy</span> should be explained.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e71cfafa-793b-4d7d-bf72-cddc9da78fe7"></a><a name="section-7.2.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Pregnancy Wastage and Birth Anomalies:</span> The physician should explain the assumed risk of any pregnancy, whether ovulation is induced with the aid of clomiphene citrate tablets USP or occurs naturally. The patient should be informed of the greater risks associated with certain characteristics or conditions of any pregnant woman, eg., age of female and male partner, history of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, Rh genotype, abnormal menstrual history, <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> history, organic heart disease, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, exposure to infectious agents such as <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, familial history of birth anomaly, that may be pertinent to the patient for whom clomiphene citrate tablets USP is being considered. Based upon the evaluation of the patient, genetic counseling may be indicated.</p>
<p>The overall incidence of reported birth anomalies from pregnancies associated with maternal clomiphene citrate tablets USP ingestion during the investigational studies was within the range of that reported in published references for the general population. (See <a href="#LINK_e3fe5241-bacc-4a55-bb7c-81e8af4461ca">CONTRAINDICATIONS: Pregnancy</a>.)</p>
<p>During clinical investigation, the experience from patients with known pregnancy outcome (Table 1) shows a <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> rate of 20.4% and <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> rate of 1.0%. (See <a href="#LINK_0e3694f1-031f-4db7-a8bf-2346fd8de8e8">CLINICAL PHARMACOLOGY</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_8565af4b-449f-4348-a89e-1a30b6f013a3"></a><a name="section-7.3"></a><p></p>
<h2><span class="Underline">Drug Interactions</span></h2>
<p class="First">Drug interactions with clomiphene citrate tablets USP have not been documented.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_2215ae87-a6b6-46fc-814c-853014d1338f"></a><a name="section-7.4"></a><p></p>
<h2><span class="Underline">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">Long-term toxicity studies in animals have not been performed to evaluate the carcinogenic or mutagenic potential of clomiphene citrate.</p>
<p>Oral administration of clomiphene citrate tablets USP to male rats at doses of 0.3 or 1 mg/kg/day caused decreased fertility, while higher doses caused temporary <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>. Oral doses of 0.1 mg/kg/day in female rats temporarily interrupted the normal cyclic vaginal smear pattern and prevented conception. Doses of 0.3 mg/kg/day slightly reduced the number of ovulated ova and corpora lutea, while 3 mg/kg/day inhibited ovulation.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_7e26bec8-21d9-4869-9aaa-c9194e26807a"></a><a name="section-7.5"></a><p></p>
<h2><span class="Underline">Pregnancy</span></h2>
<p class="First">Pregnancy Category X. (See <a href="#LINK_ff40eb95-cda3-47eb-ae53-676800590cf2">CONTRAINDICATIONS</a>.)</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_8857d854-9f48-42fd-9ed9-9bd61246366a"></a><a name="section-7.6"></a><p></p>
<h2><span class="Underline">Nursing Mothers</span></h2>
<p class="First">It is not known whether clomiphene citrate tablets USP is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised if clomiphene citrate tablets USP is administered to a nursing woman. In some patients, clomiphene citrate tablets USP may reduce lactation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_044a5d3b-cba9-4379-9103-e7544fd16d62"></a><a name="section-7.7"></a><p></p>
<h2><span class="Underline">Ovarian Cancer</span></h2>
<p class="First">Prolonged use of clomiphene citrate tablets USP may increase the risk of a borderline or invasive ovarian tumor (see <a href="#LINK_bab349a9-eb75-4dc1-8e35-87032c0c0005">ADVERSE REACTIONS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_bab349a9-eb75-4dc1-8e35-87032c0c0005"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0b3c017f-7c10-4460-9b2d-85e92bd456ca"></a><a name="section-8.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Clinical Trial Adverse Events.</span> Clomiphene citrate tablets USP, at recommended dosages, is generally well tolerated. Adverse reactions usually have been mild and transient and most have disappeared promptly after treatment has been discontinued. Adverse experiences reported in patients treated with clomiphene citrate during clinical studies are shown in Table 2.</p>
<a name="i84886294-8bb9-454e-868c-ad83dc81da55"></a><table>
<caption><span>Table 2. Incidence of Adverse Events in Clinical Studies (Events Greater than 1%) (n = 8029*)</span></caption>
<col>
<col>
<thead><tr class="First Last">
<th class="Lrule">Adverse Event</th>
<th class="Rrule" align="center">%</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule"> <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">Ovarian Enlargement</span></td>
<td class="Rrule" align="center"> 13.6</td>
</tr>
<tr>
<td class="Lrule"> Vasomotor Flushes</td>
<td class="Rrule" align="center"> 10.4</td>
</tr>
<tr>
<td class="Lrule"> Abdominal-Pelvic <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">Discomfort</span>/<span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Distention</span>/<span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">Bloating</span></td>
<td class="Rrule" align="center"> 5.5</td>
</tr>
<tr>
<td class="Lrule"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center"> 2.2</td>
</tr>
<tr>
<td class="Lrule"> Breast <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">Discomfort</span></td>
<td class="Rrule" align="center"> 2.1</td>
</tr>
<tr>
<td class="Lrule"> Visual Symptoms</td>
<td class="Rrule" align="center"> 1.5</td>
</tr>
<tr>
<td class="Lrule">   <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, lights, <span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">floaters</span>, waves, unspecified visual complaints, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, scotomata, phosphenes </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr>
<td class="Lrule"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center"> 1.3</td>
</tr>
<tr>
<td class="Lrule"> Abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span></td>
<td class="Rrule" align="center"> 1.3</td>
</tr>
<tr class="Last">
<td class="Lrule">   Intermenstrual spotting, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span></td>
<td class="Rrule" align="center"> </td>
</tr>
</tbody>
</table>
<p>* Includes 498 patients whose reports may have been duplicated in the event totals and could not be distinguished as such. Also, excludes 47 patients who did not report symptom data.<br><br>The following adverse events have been reported in fewer than 1% of patients in clinical trails: <span class="product-label-link" type="condition" conceptid="4241033" conceptname="Acute abdomen">Acute abdomen</span>, appetite increase, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>/<span class="product-label-link" type="condition" conceptid="4194803" conceptname="Dry hair">dry hair</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">increased urinary frequency</span>/volume, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, light-headedness, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">nervous tension</span>, <span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">vaginal dryness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>/loss.</p>
<p>Patients on prolonged clomiphene citrate tablets USP therapy may show elevated serum levels of desmosterol. This is most likely due to a direct interference with <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis. However, the serum sterols in patients receiving the recommended dose of clomiphene citrate tablets USP are not significantly altered. Ovarian cancer has been infrequently reported in patients who have received fertility drugs. <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span> is a primary risk factor for ovarian cancer; however, epidemiology data suggest that prolonged use of clomiphene citrate tablets USP may increase the risk of a borderline or invasive ovarian tumor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cc97adea-6c2a-4ca1-8b48-196057668017"></a><a name="section-8.2"></a><p></p>
<h2><span class="Underline">Postmarketing Adverse Events</span></h2>
<p class="First">The following adverse experiences were reported spontaneously with clomiphene citrate tablets USP. The cause and effect relationship of the listed events to the administration of clomiphene citrate tablets USP is not known.</p>
<p><span class="Bold">Dermatologic:</span> <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="Bold">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></p>
<p><span class="Bold">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span></p>
<p><span class="Bold">Visual Disorders:</span> Abnormal accommodation, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">photopsia</span>, <span class="product-label-link" type="condition" conceptid="4088110" conceptname="Posterior vitreous detachment">posterior vitreous detachment</span>, <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span>, retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, retinal vascular spasm, temporary <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span></p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span></p>
<p><span class="Bold">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span class="Bold">Hepatic:</span> Transaminases increased, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p><span class="Bold">Neoplasms:</span> Liver (hepatic <span class="product-label-link" type="condition" conceptid="4297200" conceptname="Angiosarcoma">hemangiosarcoma</span>, liver cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span>, hepatocellular carcinoma); breast (fibrocystic disease, breast carcinoma); endometrium (endometrial carcinoma); nervous system (<span class="product-label-link" type="condition" conceptid="4298902" conceptname="Astrocytoma">astrocytoma</span>, pituitary tumor, <span class="product-label-link" type="condition" conceptid="4144527" conceptname="Prolactinoma">prolactinoma</span>, <span class="product-label-link" type="condition" conceptid="4219205" conceptname="Neurofibromatosis">neurofibromatosis</span>, <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">glioblastoma multiforme</span>, brain abcess); ovary (luteoma of pregnancy, <span class="product-label-link" type="condition" conceptid="4218306" conceptname="Dermoid cyst">dermoid cyst</span> of the ovary, ovarian carcinoma); trophoblastic (hydatiform mole, <span class="product-label-link" type="condition" conceptid="4092517" conceptname="Choriocarcinoma">choriocarcinoma</span>); miscellaneous (melanoma, <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">myeloma</span>, perianal <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span>, renal cell carcinoma, Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, tongue carcinoma, bladder carcinoma); and neoplasms of offspring (neuroectodermal tumor, <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumor</span>, <span class="product-label-link" type="condition" conceptid="4001172" conceptname="Hepatoblastoma">hepatoblastoma</span>, <span class="product-label-link" type="condition" conceptid="132853" conceptname="Lymphoid leukemia">lymphocytic leukemia</span>)</p>
<p><span class="Bold">Genitourinary:</span> <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span>, <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cyst</span> (<span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">ovarian enlargement</span> or <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> could, as such, be complicated by adnexal torsion), ovarian <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">tubal pregnancy</span>, <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span></p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p>
<p><span class="Bold">Other:</span> <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">Leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorder</span></p>
<p><span class="Bold">Fetal/Neonatal Anomalies.</span> The following fetal abnormalities have also been reported during postmarketing surveillance: delayed development; abnormal bone development including skeletal malformations of the skull, face, nasal passages, jaw, hand, limb (<span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">ectromelia</span> including amelia, <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">hemimelia</span>, and <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">phocomelia</span>), foot, and joints; tissue malformations including <span class="product-label-link" type="condition" conceptid="4002465" conceptname="Imperforate anus">imperforate anus</span>, <span class="product-label-link" type="condition" conceptid="25582" conceptname="Tracheoesophageal fistula">tracheoesophageal fistula</span>, <span class="product-label-link" type="condition" conceptid="201061" conceptname="Diaphragmatic hernia">diaphragmatic hernia</span>, <span class="product-label-link" type="condition" conceptid="194152" conceptname="Renal agenesis and dysgenesis">renal agenesis</span> and dysgenesis, and malformations of the eye and lens (<span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>), ear, lung, heart (<span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defect</span> and <span class="product-label-link" type="condition" conceptid="320835" conceptname="Tetralogy of Fallot">tetralogy of Fallot</span>), and genitalia; as well as <span class="product-label-link" type="condition" conceptid="25780" conceptname="Pituitary dwarfism">dwarfism</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, chromosomal disorders, and <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> (including <span class="product-label-link" type="condition" conceptid="377368" conceptname="Anencephalus">anencephaly</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_d3a0a9b7-eed6-4784-ac0c-db6b852808e8"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Tolerance, abuse, or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> with clomiphene citrate tablets USP has not been reported.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_6539e122-93ce-4374-9aa0-a9fd72b58313"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_87020156-7636-4a42-93b8-7312f807722b"></a><a name="section-10.1"></a><p></p>
<h2><span class="Underline">Signs and Symptoms</span></h2>
<p class="First">Toxic effects accompanying acute overdosage of clomiphene citrate tablets USP have not been reported. Signs and symptoms of overdosage as a result of the use of more than the recommended dose during clomiphene citrate tablets USP therapy include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, vasomotor flushes, visual blurring, spots or flashes, scotomata, <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">ovarian enlargement</span> with pelvic or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. (See <a href="#LINK_41434f18-61da-47c8-a54f-1e6707c620cb">CONTRAINDICATIONS: <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian Cyst</span></a>.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fa59df59-cf20-499c-9cb5-1f69bb21e082"></a><a name="section-10.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Oral LD<span class="Sub">50</span>.</span> The acute oral LD<span class="Sub">50</span> of clomiphene citrate tablets USP is 1700 mg/kg in mice and 5750 mg/kg in rats. The toxic dose in humans is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_923fd61b-d075-4389-825f-4313d5ad64ff"></a><a name="section-10.1.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Dialysis.</span> It is not known if clomiphene citrate tablets USP is dialyzable.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3be062e2-de20-43a6-8697-13873f5fef97"></a><a name="section-10.2"></a><p></p>
<h2><span class="Underline">Treatment</span></h2>
<p class="First">In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, appropriate supportive measures should be employed in addition to gastrointestinal decontamination.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_4dbb5bf6-c45e-45ec-98b1-09d6ceed5068"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_149aa9d0-682d-4514-9399-1d6bf017474f"></a><a name="section-11.1"></a><p></p>
<h2><span class="Underline">General Considerations</span></h2>
<p class="First">The workup and treatment of candidates for clomiphene citrate tablets USP therapy should be supervised by physicians experienced in management of gynecologic or <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">endocrine disorders</span>. Patients should be chosen for therapy with clomiphene citrate tablets USP only after careful diagnostic evaluation (see <a href="#LINK_a47e2626-8803-4d03-8a3a-de8f6b332ce1">INDICATIONS AND USAGE</a>). The plan of therapy should be outlined in advance. Impediments to achieving the goal of therapy must be excluded or adequately treated before beginning clomiphene citrate tablets USP. The therapeutic objective should be balanced with potential risks and discussed with the patient and others involved in the achievement of a pregnancy.</p>
<p>Ovulation most often occurs from 5 to 10 days after a course of clomiphene citrate tablets USP. Coitus should be timed to coincide with the expected time of ovulation. Appropriate tests to determine ovulation may be useful during this time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_21ae36c0-6fab-4070-b563-e2da6ec9d718"></a><a name="section-11.2"></a><p></p>
<h2><span class="Underline">Recommended Dosage</span></h2>
<p class="First">Treatment of the selected patient should begin with a low dose, 50 mg daily (1 tablet) for 5 days. The dose should be increased only in those patients who do not ovulate in response to cyclic 50 mg clomiphene citrate tablets USP. A low dosage or duration of treatment course is particularly recommended if unusual sensitivity to pituitary gonadotropin is suspected, such as in patients with <span class="product-label-link" type="condition" conceptid="195501" conceptname="Polycystic ovaries">polycystic ovary</span> syndrome (see <a href="#LINK_9c02db35-383e-45c4-b6ea-9a39d6a5bd55">WARNINGS; <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian Hyperstimulation Syndrome</span></a>).</p>
<p>The patient should be evaluated carefully to exclude pregnancy, <span class="product-label-link" type="condition" conceptid="4281817" conceptname="Large ovary">ovarian enlargement</span>, or <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cyst</span> formation between each treatment cycle.</p>
<p>If progestin-induced <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is planned, or if spontaneous <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> occurs prior to therapy, the regimen of 50 mg daily for 5 days should be started on or about the 5th day of the cycle. Therapy may be started at any time in the patient who has had no recent <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>. When ovulation occurs at this dosage, there is no advantage to increasing the dose in subsequent cycles of treatment.</p>
<p>If ovulation does not appear to occur after the first course of therapy, a second course of 100 mg daily (two 50 mg tablets given as a single daily dose) for 5 days should be given. This course may be started as early as 30 days after the previous one after precautions are taken to exclude the presence of pregnancy. Increasing the dosage or duration of therapy beyond 100 mg/day for 5 days is not recommended. </p>
<p>The majority of patients who are going to ovulate will do so after the first course of therapy. If ovulation does not occur after three courses of therapy, further treatment with clomiphene citrate tablets USP is not recommended and the patient should be reevaluated. If three ovulatory responses occur, but pregnancy has not been achieved, further treatment is not recommended. If menses does not occur after an ovulatory response, the patient should be reevaluated. Long-term cyclic therapy is not recommended beyond a total of about 6 cycles (see <a href="#LINK_fe21a01b-de53-4a61-a2cc-93ab8837a65b">PRECAUTIONS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_5748a7e4-f6a8-4aef-b4a0-237c57b5448d"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">50 mg tablets in cartons of 30</p>
<p>Tablets are round, white, scored, and debossed <span class="Bold">Watson</span> over <span class="Bold">781</span>.</p>
<p>Store tablets at controlled room temperature 59°-86°F (15°-30°C). Protect from heat, light, and excessive humidity, and store in closed containers.</p>
<p><span class="Bold">Manufactured for:</span><br>Watson Laboratories, Inc.<br>Corona, CA 92880 USA</p>
<p><span class="Bold">Manufactured by:</span><br>Patheon Pharmaceuticals Inc.<br>Cincinnati, OH 45215 USA</p>
<p>Revised: June 2004                                                         70010587</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_0eaadca2-04b0-4b14-b7b4-5458b6f0e8ac"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><br>Clomiphene Citrate <br>Tablets USP<br>50 mg<br>Rx only<br>                                    <br> </p>
<div class="Figure"><img alt="43063250 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53eff40f-37b1-47b1-a9b8-c22360855f18&amp;name=43063250.jpg"></div>
<br>PDRx Label<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLOMIPHENE CITRATE 		
					</strong><br><span class="contentTableReg">clomiphene citrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43063-250(NDC:0591-0781)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLOMIPHENE CITRATE</strong> (CLOMIPHENE) </td>
<td class="formItem">CLOMIPHENE CITRATE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">watson;781</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:43063-250-05</td>
<td class="formItem">5  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016131</td>
<td class="formItem">02/01/1967</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack(43063-250)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7c88e727-566c-47ea-9bb0-76b52e2d987f</div>
<div>Set id: 53eff40f-37b1-47b1-a9b8-c22360855f18</div>
<div>Version: 4</div>
<div>Effective Time: 20120716</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
